JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78

Benzinga · 2d ago
JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $70 to $78.